Literature DB >> 3889119

Pre-clinical toxicology of nitazoxanide--a new antiparasitic compound.

J R Murphy, J C Friedmann.   

Abstract

The acute and subchronic toxicological effects of nitazoxanide were investigated at levels near and in excess of the therapeutic dose in rats, mice, dogs and cats. Single oral gavage doses of 0.625-10 g per kg body weight were administered to rats and mice. Single oral doses of 1-10 g per kg body weight were administered in capsules to dogs and cats. Acute oral LD50 values were greater than 10 g kg-1 in rats, dogs and cats, and 1.4 g kg-1 in mice. Systemic toxicity was evaluated in a repeated dose study in rats at doses of 50, 150 and 450 mg per kg per day for 14 weeks. The highest dose group exhibited intense salivation, increased liver and spleen weight, and decreased thymus weights. Variances between control and treated organ weights were not confirmed by histopathological evaluation. Nitazoxanide was negative when tested in the Ames Salmonella assay using five tester strains with and without metabolic activation at levels from 1 to 100 mg per plate. The drug was also shown to be non-irritating in a test for eye irritation potential.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3889119     DOI: 10.1002/jat.2550050202

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  9 in total

1.  In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

Authors:  C S McVay; R D Rolfe
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice.

Authors:  Fengfeng Li; Man Jiang; Minghui Ma; Xuyang Chen; Yidan Zhang; Yixin Zhang; Yuanyuan Yu; Yunfeng Cui; Jiahui Chen; Hui Zhao; Zhijie Sun; Deli Dong
Journal:  Acta Pharm Sin B       Date:  2021-09-17       Impact factor: 14.903

3.  Efficacy of nitazoxanide against experimental cryptosporidiosis in goat neonates.

Authors:  Henri Viel; Hélène Rocques; Jennifer Martin; Christophe Chartier
Journal:  Parasitol Res       Date:  2007-09-15       Impact factor: 2.289

4.  Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.

Authors:  B L Blagburn; K L Drain; T M Land; R G Kinard; P H Moore; D S Lindsay; D A Patrick; D W Boykin; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

5.  Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

Authors:  F Mégraud; A Occhialini; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Simultaneous spectrophotometric estimation of nitazoxanide and ofloxacin in tablets.

Authors:  Madhuri D Game; D M Sakarkar
Journal:  Indian J Pharm Sci       Date:  2011-01       Impact factor: 0.975

7.  Efficacy of nitazoxanide to treat natural Giardia infections in dogs.

Authors:  Mario Moron-Soto; Lilia Gutierrez; Héctor Sumano; Graciela Tapia; Yazmin Alcala-Canto
Journal:  Parasit Vectors       Date:  2017-01-31       Impact factor: 3.876

8.  Simultaneous voltammetric determination of nitazoxanide and ofloxacin in pharmaceutical formulation.

Authors:  Shital Gandhi; V Mehta; Sadhana Rajput
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

9.  Identification of PPARγ ligands with One-dimensional Drug Profile Matching.

Authors:  Diána Kovács; Zoltán Simon; Péter Hári; András Málnási-Csizmadia; Csaba Hegedűs; László Drimba; József Németh; Réka Sári; Zoltán Szilvássy; Barna Peitl
Journal:  Drug Des Devel Ther       Date:  2013-09-02       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.